Literature DB >> 11768026

Pulmonary tuberculosis in Kumasi, Ghana: presentation, drug resistance, molecular epidemiology and outcome of treatment.

S D Lawn1, E H Frimpong, H Al-Ghusein, J W Acheampong, A H Uttley, P D Butcher, G E Griffin.   

Abstract

To assist implementation of tuberculosis (TB) control measures, knowledge of the disease characteristics in a community is essential. This study in Kumasi, Ghana, correlates the clinical presentation, microbiology, molecular epidemiology and clinical outcome of thirty consecutively diagnosed patients with new smear-positive pulmonary TB. Several important factors that potentially promote disease transmission in the community were identified: patients had prolonged duration of productive cough prior to diagnosis (mean=4.1 months; SD=2.1); the disease was typically advanced at presentation and Ziehl-Neelson sputum smears indicated a high bacterial load (80% graded > AFB++); home accommodation was overcrowded with a mean of 3.3 other persons sleeping in the same room as the patients at night. IS6110 restriction fragment length polymorphism (RFLP) fingerprinting of 25 isolated (23 Mycobacterium tuberculosis and 2 Mycobacterium africanum) from epidemiologically unrelated cases identified 3 identical strains and 3 clusters containing 2, 4 and 8 isolates of > or =80% similarity, suggesting high rates of disease transmission. A high prevalence of primary resistance to isoniazid was found (6 out 26; 23%) but resistance to rifampicin, pyrazinamide, ethambutol, streptomycin and ciprofloxacin was not detected. Smear coversion at 2 months and final outcome of treatment with short courses chemotherapy were independent of isoniazid resistance, but the rate of treatment default was unacceptably high (37%). High rates of disease transmission, primary isoniazid resistance and treatment default all indicate poor TB control. The use of rifampicin-containing short-course chemotherapy in this community must be accompanied by adequate resources and infrastructure to ensure very stringent treatment supervision to improve case-holding and reduce the risk of multi-drug resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768026

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  6 in total

1.  Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study.

Authors:  Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour
Journal:  BMJ Open       Date:  2022-07-05       Impact factor: 3.006

2.  Mycobacterial species causing pulmonary tuberculosis at the korle bu teaching hospital, accra, ghana.

Authors:  Kk Addo; K Owusu-Darko; D Yeboah-Manu; P Caulley; M Minamikawa; F Bonsu; C Leinhardt; P Akpedonu; D Ofori-Adjei
Journal:  Ghana Med J       Date:  2007-06

3.  Mycobacterium tuberculosis drug resistance, Ghana.

Authors:  Ellis Owusu-Dabo; Ohene Adjei; Christian G Meyer; Rolf D Horstmann; Anthony Enimil; Thomas F Kruppa; Frank Bonsu; Edmund N L Browne; Margaret Amanua Chinbuah; Ivy Osei; John Gyapong; Christof Berberich; Tanja Kubica; Stefan Niemann; Sabine Ruesch-Gerdes
Journal:  Emerg Infect Dis       Date:  2006-07       Impact factor: 6.883

Review 4.  Antibiotic resistance patterns in human, animal, food and environmental isolates in Ghana: a review.

Authors:  Pilar García-Vello; Bruno González-Zorn; Courage Kosi Setsoafia Saba
Journal:  Pan Afr Med J       Date:  2020-02-12

5.  Microscopic Observation Drug Susceptibility (MODS) Assay: A Convenient Method for Determining Antibiogram of Clinical Isolates of Mycobacterium tuberculosis in Ghana.

Authors:  Enid Owusu; Mercy Jemima Newman
Journal:  Med Sci (Basel)       Date:  2020-01-25

6.  Molecular epidemiology and multidrug resistance of Mycobacterium tuberculosis complex from pulmonary tuberculosis patients in the Eastern region of Ghana.

Authors:  Benjamin D Thumamo Pokam; Dorothy Yeboah-Manu; Daniel Amiteye; Prince Asare; Prisca Wabo Guemdjom; Nchawa Yangkam Yhiler; Samuel Nii Azumah Morton; Stephen Ofori-Yirenkyi; Roger Laryea; Roger Tagoe; Anne Ebri Asuquo
Journal:  Heliyon       Date:  2021-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.